Meiji snaps India's Medreich in face of 'Ranbaxy syndrome'
This article was originally published in Scrip
Executive Summary
Japan's Meiji group has acquired the Indian contract development and manufacturing firm Medreich for $290m catapulting its plans to develop a competitive play in the generics business and expand in Asia and other emerging markets.